目的 研究鼻渊通窍颗粒联合匹多莫德治疗儿童过敏性鼻炎的临床疗效。方法 选取2015年2月-2017年2月海口市中医医院收治的86例过敏性鼻炎患者，随机分为对照组和治疗组，每组各43例。对照组口服匹多莫德口服液，1支/次，2次/d。治疗组在对照组治疗基础上口服鼻渊通窍颗粒，15 g/次，3次/d。两组均连续治疗3个月。观察两组的临床疗效，比较两组治疗前后临床症状积分、屋尘螨变应原的血清特异性IgE滴度、鼻腔气流、鼻孔解剖区面积及血清细胞因子的变化情况。结果 治疗后，对照组和治疗组的总有效率分别为81.40%、93.02%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组临床症状积分、吸气相和呼气相气流阻力、Der p1和Der p2血清特异性IgE滴度均较治疗前显著降低，鼻孔解剖区面积明显升高，同组治疗前后差异有统计学意义（P<0.05）；治疗后，治疗组患者临床症状积分、吸气相和呼气相气流阻力、Der p1和Der p2血清特异性IgE滴度显著低于对照组，鼻孔解剖区面积高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组IL-10、IL-8和sICAM-1均较治疗前显著增加，同组治疗前后差异有统计学意义（P<0.05）。治疗后，治疗组IL-10、IL-8和sICAM-1显著高于对照组，两组比较差异有统计学意义（P<0.05）。结论 鼻渊通窍颗粒联合匹多莫德治疗过敏性鼻炎具有较好的临床疗效，可明显缓解过敏性鼻炎的临床症状，降低鼻腔气流阻力，降低过敏性IgE抗体效价，有效缓解炎症反应，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Biyuan Tongqiao Granules combined with pidotimod in treatment of children with allergic rhinitis. Methods Children (86 cases) with allergic rhinitis in Haikou Traditional Chinese Medicine Hospital from February 2015 to February 2017 were randomly divided into control and treatment groups, and each group had 43 cases. Children in the control group were po administered with Pidotimod Oral Solution, 1 bottle/time, twice daily. Children in the treatment group were po administered with Biyuan Tongqiao Granules on the basis of the control group, 15 g/time, three times daily. Children in two groups were treated for 3 months. After treatment, clinical efficacy was evaluated, and the changes of the clinical symptom scores, serum specific IgE titer of the dust mite allergen, nasal airflow, anatomic area, and serum cytokines in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.40% and 93.02%, respectively, and there was difference between two groups (P<0.05). After treatment, the clinical symptom scores, inhalation phase and expiratory phase flow resistance, Der p1 and Der p2 serospecific IgE titers in two groups obviously decreased, but anatomic area of the nostril was significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the clinical symptom scores, inhalation phase and expiratory phase flow resistance, Der p1 and Der p2 serospecific IgE titers in the treatment group were lower than those in the control group, but anatomic area of the nostril was higher than that in the control group, and there was difference between two groups (P<0.05). After treatment, the levels of IL-10, IL-8, and sICAM-1 in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the levels of IL-10、IL-8 and sICAM-1 in the treatment group were higher than those in the control group, and there was difference between two groups (P<0.05). Conclusion Biyuan Tongqiao Granules combined with pidotimod has good clinical effect in treatment of children with allergic rhinitis, and can obviously relieve the clinical symptoms of allergic rhinitis, also can reduce nasal airflow resistance and allergic IgE antibody titer, and can alleviate the inflammatory response effectively, which has a certain clinical application value.